NewsRx

Search our medical news database

Avicena Group, Inc.

Avicena receives patent governing Creatine's use in healthcare applications

Published in Medicine and Law Weekly, May 19th, 2006

The Avicena Group, Inc., (AVGO) a developer of novel pharmaceutical and therapeutic products, announced that it has been granted a patent entitled, "Use of Creatine or Creatine Compounds for Skin Preservation" from the Commonwealth of Australia's Patent Office.

This patent, number 09/344427, further strengthens Avicena's intellectual property portfolio, particularly as it relates to the company's growing dermaceutical business. Avicena has already secured patent protection for this use in the United States (U.S. 6,242,491 B1) and a similar patent application is presently pending in Europe.

Avicena possesses a substantial intellectual property...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook